Wondering Why Omnicell Fell? Here's What Bears Saw

If you had backed Omnicell at the start of 2026, the payoff so far would feel uncomfortable. Investors who held Omnicell from the start of the year are down 20.5%, including dividends. That retreat sits against a backdrop of bullish talk about an aging population, medication automation and a higher recurring SaaS mix, alongside more cautious worries about government cost controls and cybersecurity costs. Which of those original assumptions about growth, profit margins and elevated P/E expectations proved too optimistic, and which still look intact?

This theme extends beyond Omnicell. See which of 36 healthcare AI stocks may still merit a closer look.

The Argument You Would Have Been Weighing Up On Omnicell

The shares cost US$45.3 at the start of the period, and the debate around Omnicell split into two clear stories about what might come next.

The bullish case pinned a Fair Value of US$55, a price those assumptions suggested could be justified, on 5.2% revenue growth and profit margins rising to 2.7% as OmniSphere and other SaaS tools shifted the mix toward recurring software.

The bearish view set Fair Value at US$34 based on 2.5% revenue growth, profit margins at 2.9%, and a belief that government cost controls plus rising cybersecurity spending would cap the benefit of that same cloud transition.

What The Evidence Around Omnicell Actually Tested

The Q3 2026 report showed Omnicell’s revenue at US$307.9m compared with US$310.6m a year earlier, which pushed against the bullish growth story. Net income rose to US$11m and net margin reached 3.6% versus 1.8%, so profitability moved closer to both camps’ assumptions. Taken together, the evidence cut both ways.

The useful takeaway is simple. When a thesis hinges on a richer SaaS mix, keep checking whether net margin and recurring revenue share move toward the forecast, even if headline sales stall.

What You Would Be Paying For In Omnicell Today

Omnicell now trades at US$35.9, with the year to date return from the start of the year still down 20.5%. The bearish analyst Narrative on Simply Wall St sees Fair Value above that level, based on a specific reading of the guidance and refreshed product cycle.

That Narrative leans on the idea that higher EBITDA guidance and a growing recurring software and services mix eventually matter more than bookings uncertainty and margin pressure. For that higher figure to be reached, a buyer today would need to believe the Titan XT and OmniSphere refresh turns the larger pipeline into durable, higher margin revenue.

"The main thing that has to go right is that the Titan XT and OmniSphere refresh, along with growing specialty pharmacy and cloud service revenues, turns the current larger bookings pipeline and higher EBITDA guidance into a durable shift toward higher margin recurring revenue."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Find Your Own Contrarian Opportunity

The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.

• Company 1 - 25% below our estimate - targets fast-growing AI data center optics and new capacity builds.
• Company 2 - 39% below our estimate - tightens carrier screening and applies AI analytics to reduce fraud exposure.
• Company 3 - 43% below our estimate - rolls out cash recycling machines and modular branches to streamline transactions.

Three companies from the same screener. Open all 35 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com